Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer

KRAS-driven lung cancers frequently inactivate TP53 and/or STK11/LKB1, defining tumor subclasses with emerging clinical relevance. Specifically, KRAS-LKB1 (KL) mutant lung cancers are particularly aggressive, lack PD-L1, and respond poorly to immune checkpoint blockade (ICB). The mechanistic basis f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Kitajima, Shunsuke, Ivanova, Elena, Guo, Sujuan, Yoshida, Ryohei, Campisi, Marco, Sundararaman, Shriram K., Tange, Shoichiro, Mitsuishi, Yoichiro, Thai, Tran C., Masuda, Sayuri, Piel, Brandon P., Sholl, Lynette M., Kirschmeier, Paul T., Paweletz, Cloud P., Watanabe, Hideo, Yajima, Mamiko, Barbie, David A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6328329/
https://ncbi.nlm.nih.gov/pubmed/30297358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-0689
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados